Le Lézard
Classified in: Health, Science and technology, Business
Subjects: CON, TRI

BenevolentAI achieves third milestone in its AI-enabled drug discovery collaboration with AstraZeneca


LONDON, May 17, 2022 /PRNewswire/ -- BenevolentAI (Euronext Amsterdam: BAI), a leading clinical-stage AI-enabled drug discovery company, today announces that AstraZeneca has selected an additional novel target for idiopathic pulmonary fibrosis (IPF) for its drug development portfolio, resulting in a milestone payment to BenevolentAI.

This is the third novel target from the collaboration that has been identified using the Benevolent Platformtm across two disease areas, IPF and chronic kidney disease, and subsequently validated and selected for portfolio entry by AstraZeneca. This builds upon the recent extension of the collaboration with AstraZeneca to include two new disease areas, systemic lupus erythematosus and heart failure, signed in January 2022.

The Benevolent Platformtm is a disease-agnostic AI-enabled drug discovery platform that is capable of generating novel targets at scale. As part of the collaboration, BenevolentAI integrated AstraZeneca's data into its biomedical Knowledge Graph, which includes proprietary, public and licensed data from a variety of sources including, but not limited to, scientific literature, patents, genetics, chemistry and clinical trials. BenevolentAI and AstraZeneca scientists work side-by-side, using the platform and Knowledge Graph to interrogate the underlying mechanisms of IPF, to frame and test hypotheses and rapidly identify novel targets.

Professor Maria Belvisi, SVP and Head of Research and Early Development, Respiratory and Immunology at AstraZeneca commented: "IPF is a devastating disease with median survival of around 3 years and there is a serious need for better treatment options. At AstraZeneca, we are continuously striving to improve our R&D productivity in order to quickly bring potentially innovative treatments to complex diseases such as IPF. Our partnership with BenevolentAI furthers our commitment and we are proud to deliver a second novel target for IPF to our portfolio."

Dr Anne Phelan, Chief Scientific Officer at BenevolentAI commented: "Target identification is an essential first step in the drug discovery pipeline, and where we believe the Benevolent Platformtm can make the biggest impact. Our AI-enabled approach empowers scientists to explore all the available evidence to unravel the enormous complexity of biological systems and the underlying mechanisms of disease. By reaching this third milestone, we have further validated the ability of BenevolentAI's disease agnostic platform to identify novel targets and deliver tangible scientific results for complex and debilitating conditions such as IPF."

ABOUT BENEVOLENTAI 
BenevolentAI (AMS: BAI) is a leading, clinical-stage AI-enabled drug discovery company listed on the Euronext Amsterdam stock exchange. Through the combined capabilities of its AI platform, scientific expertise, and wet-lab facilities, BenevolentAI is well-positioned to deliver novel drug candidates with a higher probability of clinical success than those developed using traditional methods. BenevolentAI has a consistently proven track record of scientifically validated discoveries. The BenevolentAI Platformtm powers a growing in-house pipeline of over 20 drug programmes, spanning from target discovery to clinical studies, and it maintains successful collaborations with AstraZeneca, as well as leading research and charitable institutions. BenevolentAI is headquartered in London, with a research facility in Cambridge (UK) and a further office in New York.

Logo - https://mma.prnewswire.com/media/1725546/Benevolent_Logo.jpg


These press releases may also interest you

at 10:30
The Public Health Agency of Canada (PHAC) is issuing this statement to provide an update on its ongoing response to monkeypox. PHAC continues to work closely with provinces and territories to ensure collaboration and coordination of Canada's...

at 10:30
Compass Surgical Partners announced a partnership with local physicians and Bon Secours St. Francis Hospital in Greenville, S.C. Millennium Surgery Center will offer orthopaedic, spine and ENT procedures, along with robotic outpatient joint...

at 10:30
The "Global CFTR Modulators Market Opportunity, Dosage, Price & Clinical Trials Insight 2028" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insight on clinical and non-clinical factors that are driving...

at 10:30
"I wanted to create a storage accessory for face masks to keep them safe and accessible," said an inventor, from Spring, Texas, "so I invented the MASK CASE. My design would eliminate the need to put your mask in a pocket or on an unsanitary...

at 10:20
A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled "Fundus Cameras - Global Market Trajectory & Analytics". The report presents fresh perspectives on...

at 10:07
Fresh Start Surgical Gifts has partnered with Sanford Health to expand their services and further their mission to transform the lives of children and teens forever. Fresh Start recently hosted free informational sessions on services offered in Sioux...



News published on 17 may 2022 at 01:00 and distributed by: